Press releases
- REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients
- REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II
- REGENXBIO Announces Leadership Transition
- REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Reports First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Host Conference Call on May 8 to Discuss First Quarter 2024 Financial Results and Recent Operational Highlights
- REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
More ▼
Key statistics
On Monday, Regenxbio Inc (RB0:FRA) closed at 11.50, 19.17% above the 52 week low of 9.65 set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 11.50 |
---|---|
High | 11.50 |
Low | 11.50 |
Bid | -- |
Offer | -- |
Previous close | 11.50 |
Average volume | 92.00 |
---|---|
Shares outstanding | 49.26m |
Free float | 45.65m |
P/E (TTM) | -- |
Market cap | 654.12m USD |
EPS (TTM) | -5.88 USD |
Data delayed at least 15 minutes, as of Jul 22 2024 07:10 BST.
More ▼